150 related articles for article (PubMed ID: 25994489)
1. Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices.
Peria M; Donnadieu J; Racz C; Ikoli JF; Galmiche A; Chauffert B; Page C
Head Neck; 2016 Apr; 38 Suppl 1():E911-5. PubMed ID: 25994489
[TBL] [Abstract][Full Text] [Related]
2. Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.
Donnadieu J; Lachaier E; Peria M; Saidak Z; Dakpe S; Ikoli JF; Chauffert B; Page C; Galmiche A
BMC Cancer; 2016 Apr; 16():273. PubMed ID: 27085492
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Michel L; Ley J; Wildes TM; Schaffer A; Robinson A; Chun SE; Lee W; Lewis J; Trinkaus K; Adkins D
Oral Oncol; 2016 Jul; 58():41-8. PubMed ID: 27311401
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab and the Head and Neck Squamous Cell Cancer.
Concu R; Cordeiro MNDS
Curr Top Med Chem; 2018; 18(3):192-198. PubMed ID: 29332581
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
[TBL] [Abstract][Full Text] [Related]
6. A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development.
Gronbach L; Wolff C; Klinghammer K; Stellmacher J; Jurmeister P; Alexiev U; Schäfer-Korting M; Tinhofer I; Keilholz U; Zoschke C
Biomaterials; 2020 Nov; 258():120277. PubMed ID: 32795620
[TBL] [Abstract][Full Text] [Related]
7. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra R; Cohen RB; Burtness BA
Clin Adv Hematol Oncol; 2008 Oct; 6(10):742-50. PubMed ID: 18997665
[TBL] [Abstract][Full Text] [Related]
8. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
10. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
12. Anti- or pro-proliferation—conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.
Ekblad L; Welinder C; Kjellén E; Brun E; Wennerberg J
Oral Oncol; 2015 Jan; 51(1):46-52. PubMed ID: 25261297
[TBL] [Abstract][Full Text] [Related]
13. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance.
Gerlach MM; Merz F; Wichmann G; Kubick C; Wittekind C; Lordick F; Dietz A; Bechmann I
Br J Cancer; 2014 Jan; 110(2):479-88. PubMed ID: 24263061
[TBL] [Abstract][Full Text] [Related]
14. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
Pointreau Y; Azzopardi N; Ternant D; Calais G; Paintaud G
Ther Drug Monit; 2016 Oct; 38(5):567-72. PubMed ID: 27631463
[TBL] [Abstract][Full Text] [Related]
16. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
17. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
Zhang N; Erjala K; Kulmala J; Qiu X; Sundvall M; Elenius K; Grénman R
Radiother Oncol; 2009 Sep; 92(3):388-92. PubMed ID: 19447510
[TBL] [Abstract][Full Text] [Related]
18. Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab.
Baxi SS; O'Neill C; Sherman EJ; Atoria CL; Lee NY; Pfister DG; Elkin EB
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E165-71. PubMed ID: 25535104
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial cetuximab for the treatment of recurrent unresectable head and neck squamous cell carcinoma
Tham T; White TG; Chakraborty S; Lall RR; Ortiz R; Langer DJ; Shatzkes D; Filippi CG; Kraus D; Boockvar JA; Costantino PD
J Exp Ther Oncol; 2016 Nov; 11(4):293-301. PubMed ID: 27849340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]